1073 related articles for article (PubMed ID: 34109900)
1. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine development: What lessons can we learn from TB?
Safar HA; Mustafa AS; McHugh TD
Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):56. PubMed ID: 33256750
[TBL] [Abstract][Full Text] [Related]
6. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
[TBL] [Abstract][Full Text] [Related]
7. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
8. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
Front Immunol; 2021; 12():771242. PubMed ID: 34880867
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
11. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
12. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccines: ethical framework concerning human challenge studies.
Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
[TBL] [Abstract][Full Text] [Related]
14. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
15. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
Mudgal R; Nehul S; Tomar S
Hum Vaccin Immunother; 2020 Dec; 16(12):2921-2931. PubMed ID: 32931361
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects.
Wong RSY
Malays J Pathol; 2021 Aug; 43(2):203-217. PubMed ID: 34448786
[TBL] [Abstract][Full Text] [Related]
17. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches.
Marei HE; Althani A; Afifi N; Pozzoli G; Caceci T; Angelini F; Cenciarelli C
Mol Biol Rep; 2021 Sep; 48(9):6513-6524. PubMed ID: 34398427
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.
Ita K
Arch Med Res; 2021 Jan; 52(1):15-24. PubMed ID: 32950264
[TBL] [Abstract][Full Text] [Related]
19. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
20. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
Jin Y; Hou C; Li Y; Zheng K; Wang C
Front Immunol; 2021; 12():821538. PubMed ID: 35126377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
